Bristol Seeking Two NDAs For UFT Combos In Response To Rebetron Debate

Bristol-Myers Squibb's submission of two separate NDAs for the combination use of UFT and leucovorin appears to be a new filing and approval strategy for the development of bundled multi-ingredient products.